Researchers at Rutgers University have uncovered a new way to stimulate activity of immune cell opiate receptors, leading to efficient tumor cell clearance.
Dipak Sarkar, professor in the Department of Animal Sciences at the Rutgers School of Environmental and Biological Sciences and his research team have been able to take a new pharmacological approach to activate the immune cells to prevent cancer growth through stimulation of the opiate receptors found on immune cells.This research, funded by the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholosm, is featured on the cover of the May 11 issue of the Journal of Biological Chemistry. It describes two structurally different but functionally similar opioid receptors, Mu- and Delta-opioid receptors. These receptors form protein complexes as either two structurally similar receptors as a homodimer—formed by two identical molecules—or two structurally dissimilar protein complexes as a heterodimer—formed by ethanol inducement—in immune cells. The team pharmacologically fooled these two structurally different but functionally similar opioid receptors to form more homodimers so that opioid peptide increases the immune cells’ ability to kill tumor cells.
Opioids, like endorphins, communicate with the immune system, so when there is a deficit of endorphin – due to fetal alcohol exposure, alcoholism and drug abuse, anxiety, depression and chronic psychological stress – the body undergoes stress shocks and, as Sarkar suggests, causes “immune incompetence.”
“Opioids act as the regulator of body stress mechanism, so when endorphins are low, body stress indicators are high,” says Sarkar, who directs the Endocrine Research Program at Rutgers and is a faculty member of the Rutgers Center of Alcohol Studies.
“What’s new about this latest research is that when we combine the Mu receptor blocker (antagonist) with the Delta receptor stimulator (agonist), the immune cells accrue increased foreign cell-killing ability,” explains Sarkar. “This makes the body highly effective in fighting against bacterial infection and tumor growth.”
Sarkar believes that combining this opioid antagonist and agonist may have potential therapeutic value in humans for the treatment of immune incompetence, cancer, pain and ethanol-dependent diseases.
Previous research by the Sarkar group showed that replenishing endorphins by cell therapy did prevent many of the stress and immune problems in fetal alcohol-exposed test subjects. However, cell therapy is highly complex, involving the cumbersome process of producing endorphin cells from neural stem cells of patients and can sometimes result in rejection and other issues.
The beginning of the team’s interest into how stress causes diseases started with the observation that mothers who suffer from alcohol abuse or with other developmental problems often give birth to children who exhibited hype-stress responses, linked to childhood disease, child abnormality, immune diseases and cancer.
As part of their investigation, the Sarkar research team learned that the endogenous opioid system in the brain is abnormal in kids and adults who demonstrate hyper-stress responses.
“With the link between hyper-stress responses and manifested immune issues, the goal has been to replenish the opioid deficit in the brain and lead to an effective therapy for immune and other diseases,” explained Sarkar.
The team also found that when people consume alcohol, the effectiveness of the body’s ability to defend against viral and bacterial invasion, and fight against cancer decreases.“The overall goal of our research program is to increase our understanding of and develop new therapy for the treatment of cancer, immune and other alcoholism-induced diseases,” says Sarkar.
Paula Walcott-Quintin | EurekAlert!
Molecular doorstop could be key to new tuberculosis drugs
20.03.2018 | Rockefeller University
Modified biomaterials self-assemble on temperature cues
20.03.2018 | Duke University
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
20.03.2018 | Agricultural and Forestry Science
20.03.2018 | Life Sciences
20.03.2018 | Life Sciences